• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Semaglutide and phentermine-topiramate are effective weight reducing medications

byJessie WillisandTeddy Guo
February 2, 2022
in Chronic Disease, Endocrinology, Gastroenterology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. GLP-1 receptor agonists, such as semaglutide, and phentermine-topiramate were shown to cause the greatest percent decrease in body weight.

2. GLP-1 receptor agonists, phentermine-topiramate, and naltrexone-bupropion were also associated with increased adverse effects.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Over two-thirds of Americans are considered to be in the overweight or obese body-mass index (BMI) ranges. Despite this, there are limited pharmacotherapy options for weight loss when lifestyle interventions are not sufficient. This systematic review selected randomized control trials (RCTs) which evaluated weight lowering drugs versus lifestyle modification. A total of 143 studies were identified. Of the drugs studied, phentermine-topiramate and GLP-1 receptor agonists demonstrated the highest efficacy for lowering total body weight. However, these drugs, along with naltrexone-bupropion were associated with the greatest number of adverse events leading to discontinuation. Of all the drugs, semaglutide (a GLP-1 receptor agonist) showed the greatest benefit with a similar risk of adverse events as the other drugs. Limitations of this study include the heterogeneity of the study populations, but no differences were seen across baseline BMI, follow-up durations and co-morbid diabetes. Nonetheless, this study provides high quality evidence regarding pharmacotherapy options for weight loss.

Click to read the study in the Lancet

Relevant Reading: Once-Weekly Semaglutide in Adults with Overweight or Obesity

In-Depth [systematic review and meta-analysis]: This systematic review identified eligible RCTs that evaluated lifestyle modifications versus pharmacotherapy in overweight or obese adults. The studies must have recorded absolute or percentage weight change after at least 12 weeks of treatment. Exclusion criteria included studies relating to psychiatric conditions including schizophrenia. 143 RCTs (n = 49810) were selected after full text review. The median age of participants was 47 with 75% female and an average BMI of 35.3 at baseline. The drugs identified included GLP-1 agonists, SGLT2 inhibitors, metformin, orlistat, naltrexone-bupropion, pramlintide, and levocarnitine. All drugs except levocarnitine reduced body weight except levocarnitine. All drugs except metformin, SGLT2 inhibitors and pramlintide led to greater than 10% decrease in weight in the majority of participants. The greatest mean difference of percent body weight change was seen with semaglutide (-11.41%, 95% CI -12.54 to -10.27) and phentermine-topiramate (-7.97%, 95% CI -9.28 to -6.66). However, the drugs with the greatest risk (odds ratio) of discontinuation due to adverse events were semaglutide (Odds ratio 2.45), naltrexone-bupropion (2.69), and phentermine-topiramate (2.40).

RELATED REPORTS

Time restricted eating not more beneficial than daily calorie restriction

Adequate sleep may reduce energy intake and weight in overweight adults

Wellness Check: Nutrition

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: body mass index (BMI)buproprionGLP-1 agonistNaltrexonenaltrexone-buproprionobeseorlistatoverweightphentermine-topiramatesemaglutideweight lossweight management
Previous Post

Angiotensin II receptor type 2 and 4-stimulating antihypertensives associated with reduced long-term cognitive impairment compared to receptor inhibitors

Next Post

Moderate hypothermia during venoarterial extracorporeal membrane oxygenation not associated with a decrease in 30-day mortality

RelatedReports

Sleep duration inversely related to childhood type 2 diabetes risk makers
Cardiology

Time restricted eating not more beneficial than daily calorie restriction

May 13, 2022
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Chronic Disease

Adequate sleep may reduce energy intake and weight in overweight adults

May 6, 2022
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

May 5, 2022
Cardiology

Tirzepatide is superior to insulin glargine for management of type 2 diabetes and elevated cardiovascular risk

January 11, 2022
Next Post
Parental hopes for critically ill children are dynamic

Moderate hypothermia during venoarterial extracorporeal membrane oxygenation not associated with a decrease in 30-day mortality

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Wellness Check: Addictions

#VisualAbstract: Convalescent plasma is not effective at improving clinical outcomes or reducing mortality of COVID-19 patients not on mechanical ventilation

#VisualAbstract: Ianalumab shows a dose-related improvement in disease activity in Sjögren’s syndrome without serious adverse events

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.